Use of nicotinamide riboside to treat hearing loss

Patent metadata

Field	Value
Publication number	US-9861651-B2
Application number	US-201314414924-A
Country	US
Kind code	B2
Filing date	Jul 15, 2013
Priority date	Jul 16, 2012
Publication date	Jan 9, 2018
Grant date	Jan 9, 2018

Abstract

The invention provides a method of preventing or treating hearing loss in a mammal in need thereof. The method involves administering to the mammal an agent that increases intracellular NAD+ in the mammal. The invention also provides a method of determining if a compound acts as a neuroprotective agent.

First claim

The invention claimed is:

1. A method of mitigating or treating hearing loss in a mammal in need thereof, comprising administering to the mammal an effective amount of nicotinamide riboside, thereby mitigating or treating hearing loss in the mammal, wherein the hearing loss is due to noise exposure, and wherein the nicotinamide riboside is administered to the mammal before or during exposure to the noise that causes hearing loss.

2. The method of claim 1 , wherein the nicotinamide riboside increases intracellular NAD+ in one or more cells selected from the group consisting of spiral ganglia nerve cells, inner and outer hair cells, supporting cells, and Schwann cells.

3. The method of claim 2 , wherein the nicotinamide riboside suppresses oxidative damage in the cell.

4. The method of claim 3 , wherein the nicotinamide riboside activates SIRT3.

5. The method of claim 1 , wherein the method results in mitigation of hearing loss.

6. The method of claim 1 , wherein the nicotinamide riboside is administered orally.

7. The method of claim 1 , wherein the mammal is a human or a dog.

8. The method of claim 1 , wherein nicotinamide riboside is administered by injection.

9. The method of claim 1 , wherein nicotinamide riboside is administered by intratympanic injection into the middle ear space.

Assignees

• Univ Cornell

Inventors

• Brown Kevin
• Sauve Anthony
• Jaffrey Samie

Classifications

• A61P43/00

  Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00 · CPC title

• A61P3/02

  Nutrients, e.g. vitamins, minerals · CPC title

• A61P27/16

  Otologicals · CPC title

• A61P1/08

  for nausea, cinetosis or vertigo; Antiemetics · CPC title

• G01N33/5058

  Neurological cells · CPC title